Stay updated with the latest Other news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on Other topics.
New Delhi, Apr 8 (PTI) Zydus Lifesciences Ltd on Wednesday said it has received final approval from the US health regulator for its generic version of dapagliflozin tablets indicated to control blood sugar in adults with type 2 diabetes mellitus. The approval by the US Food and Drug Administration (USFDA) is for dapagliflozin tablets of strengths 5 mg and 10 mg, Zydus Lifesciences said in a regulatory filing. Dapagliflozin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus, the company said. Zydus said it is eligible for 180 days of shared generic drug marketing exclusivity for dapagliflozin tablets, 5 mg and 10 mg. The tablets will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad, it added. Dapagliflozin tablets had annual sales of USD 10.2 billion in the US, the company said citing IQVIA MAT February 2026 data. PTI RKL DR DR
New Delhi [India], July 16 (ANI): The Indian government expressed regret on Tuesday over the reported demolition of the ancestral property of celebrated filmmaker and writer Satyajit Ray in Mymensingh, Bangladesh and expressed its willingness to extend cooperation in its restoration. "We note with profound regret that the ancestral property of noted filmmaker and litterateur Satyajit Ray in Mymensingh, Bangladesh, belonging to his grandfather and eminent litterateur, Upendra Kishor Ray Chowdhury, is being demolished," the Ministry of External Affairs said. Also Read | India Urges Bangladesh ...Read More >
If SEZ exports remain exempt, Reliance's refining margins would be largely insulated from the new levies, preserving the competitiveness of its export-oriented operations, it said New Delhi: The applicability of newly reimposed export windfall taxes on shipments of diesel and ATF from Reliance Industries' SEZ refinery remains the key uncertainty, following India's fuel duty overhaul, with significant implications for refining margins and government revenues, according to analysts. Under the rev ...Read More >
Bengaluru: Biocon Limited has achieved a regulatory milestone in the United States, reinforcing its presence in the global diabetes treatment market. Biocon Pharma Limited, a subsidiary of Biocon Limited, has received approval from the U.S. Food and Drug Administration for Dapagliflozin Tablets in 5 mg and 10 mg strengths. The approval enables the company to market the drug for adults with type 2 diabetes mellitus, expanding its footprint in one of the world's largest pharmaceutical markets. The approved drug is indicated as an adjunct to diet and exercise to improve glycemic control in adul ...Read More >
Mumbai (Maharashtra) [India], August 26: Abbott, the global healthcare company, today announced the launch of the FreeStyle Libre 2 Plus sensor, Abbott's latest addition to the FreeStyle Libre sensor portfolio. This innovative device offers automatic glucose readings every minute straight to your phone, empowering people with diabetes to manage their condition with confidence, precision, and ease. People living with diabetes can see their glucose readings, without having to scan, and receive alerts automatically on their compatible[3] smartphone when low glucose levels [4] or high glucose leve ...Read More >
Mumbai, Dec 1 (PTI) Electric vehicle maker Omega Seiki Mobility (OSM) on Monday said it is aiming to deploy 1,500 units of both cargo and passenger variants of its autonomous electric three-wheeler Swayamgati in the next 24 months as it seeks to expand its leadership position in this nascent segment. The company also announced the commercial launch of the cargo version of the vehicle, priced at Rs 4.15 lakh and said that the bookings are open from Monday, while the deliveries will commence from December itself. The launch of the vehicle brings self-driving technology to the logistics and ind ...Read More >
Mumbai (Maharashtra) [India], December 16 (ANI): Domestic stock markets continued to remain under pressure on Tuesday as both key benchmark indices opened in the red, weighed down by persistent foreign fund outflows and continued weakness in the rupee. At the opening bell, the Nifty 50 index started the day at 25,951.50, slipping by 75.80 points or 0.29 per cent. The BSE Sensex also opened lower at 85,025.61, down by 187.75 points or 0.22 per cent. Also Read | VB-G RAM G Bill 2025: 5 Key Changes in India's Rural Employment Law Replacing MGNREGA. Market participants remained cautious amid mu ...Read More >
Ahmedabad: Zydus Lifesciences has expanded its presence in the U.S. generics market with a key regulatory approval for a widely used diabetes treatment. Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration for Dapagliflozin Tablets in 5 mg and 10 mg strengths. This approval enables the company to enter the U.S. market with a generic version of the drug, broadening its portfolio in a high-demand therapeutic category. With the approval, Zydus becomes eligible for 180 days of shared generic drug exclusivity for Dapagliflozin Tablets. This li ...Read More >
New Delhi, Jul 2 (PTI) The Delhi High Court on Wednesday asked the Drug Controller General of India to consult experts and relevant stakeholders in deciding a plea over drug combinations sold in the market for weight loss treatment. A bench of Chief Justice D K Upadhyaya and Justice Tushar Rao Gedela asked the petitioner to give a representation to the DGCI, which was asked to decide the matter within three months. Also Read | 'Janaki' Title Row: Malayalam Film Industry Holds Protest in Front of CBFC Office Against Renaming of Suresh Gopi Film. A plea filed by Jitendra Chouksey said license ...Read More >
New Delhi [India], July 14 (ANI): Opening India's dairy sector to US imports could result in an annual loss of Rs 1.03 lakh crore to Indian dairy farmers, according to a recent report by the State Bank of India (SBI). The report cautioned that the move would significantly impact the livelihoods of small dairy farmers, as the US dairy sector is heavily subsidized. Also Read | Bitcoin Price Hits All-Time High Today, Cryptocurrency Surpasses USD 1,21,000 Mark for First Time. SBI stated, "If the dairy sector is opened up, price of milk in India is likely to drop by at least 15 per cent which co ...Read More >
Chandigarh: Officials of Municipal Corporation Chandigarh have revealed that the top 20 property tax defaulters of the city are yet to clear dues of over Rs 190 crore, while property tax arrear cases worth Rs 62 crore are under litigation in the Punjab and Haryana high court. Citing different reasons, occupants of seven properties, out of the top 20, have challenged the MC's arrears amount, following which the authority failed to recover the amount from them. All these properties fall under the commercial category. As per official data of the Municipal Corporation, Chandigarh, commercial prope ...Read More >
BusinessWire India Mumbai (Maharashtra) [India], August 26: Abbott, the global healthcare company, today announced the launch of the FreeStyle Libre 2 Plus sensor, Abbott's latest addition to the FreeStyle Libre sensor portfolio. This innovative device offers automatic glucose readings every minute straight to your phone, empowering people with diabetes to manage their condition with confidence, precision, and ease. People living with diabetes can see their glucose readings, without having to scan, and receive alerts automatically on their compatible[3] smartphone when low glucose levels [4] ...Read More >
New Delhi, Apr 3 (PTI) India is unlikely to be significantly impacted by US President Donald Trump's announcement of 100 per cent tariffs on certain patented drugs, as the country primarily exports low-cost generic medicines to America, think tank GTRI said on Friday. Trump signed an executive order on April 2, announcing the imposition of a 100 per cent ad valorem duty rate on the import of certain patented pharmaceuticals and associated pharmaceutical ingredients. The order, issued on April 2, 2026, builds on a Section 232 investigation launched on May 1, 2025, which cited national securit ...Read More >
New Delhi, July 14 (SocialNews.XYZ) Dietary approaches like intermittent energy restriction, time-restricted eating, and continuous energy restriction can all improve blood sugar levels and body weight in people with obesity and type 2 diabetes, according to a study. Although researchers identified improved HbA1c levels, and adverse events were similar across the three groups, the IER group showed greater advantages in reducing fasting blood glucose, improving insulin sensitivity, lowering triglycerides, and strengthening adherence to the dietary interventions. IER typically involves periods ...Read More >
New Delhi, Sep 15 (SocialNews.XYZ) India's total exports of merchandise and services clocked a robust growth of 9.34 per cent in August to $69.16 billion compared to the same month of the previous year, according to official figures released by the Commerce and Industry Ministry on Monday. The country's merchandise exports during August 2025 went up to $35.10 billion as compared to $32.89 billion in August 2024 despite the economic uncertainties in the global market triggered by the US tariff hike. "Despite global uncertainties and trade policy uncertainties, Indian exporters have done well. ...Read More >
New Delhi, Sep 26 (PTI) Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines. Reacting to the development, IPA Secretary General Sudarshan Jain said in a statement, "It is not applicable to generics medicines." Trump's statement refers to patented and branded products supplied to US, he added. In his post on social media platform Truth Social, Trump wrote, "Starting October 1st, 2025, we will be imposing a 100% Tari ...Read More >
New Delhi: US President Donald Trump's decision to impose 100% tariffs on branded and patented drug exports has shaken Indian pharmaceutical markets, despite most of India's $10 billion US sales being in generics. The uncertainty lies in whether complex generics and specialty medicines will be included, a move that could directly impact leading players like Sun Pharma, Dr. Reddy's, Cipla, Zydus Lifesciences, and others. Stocks Facing Highest Exposure Dr. Reddy's emerges as the most vulnerable, with 47% of its earnings tied to the US market, projected at $1.5 billion in FY26. Sun Pharma follo ...Read More >
New Delhi [India], September 26 (ANI): India's pharmaceutical exports are not expected to face a major impact following the recent announcement of a 100 per cent tariff on branded and patented pharmaceutical products by the US, said Sudarshan Jain, General Secretary of the Indian Pharmaceutical Alliance (IPA). Speaking to ANI on Friday, Jain said that India's exports to the US primarily consist of generic drugs and active pharmaceutical ingredients (APIs), which are not covered under this tariff. "This [100 per cent tariff on imported pharmaceutical drugs] is applicable to patented branded p ...Read More >
Mumbai: Less than a month after Ozempic maker Novo Nordisk announced it is cutting its global workforce as part of a restructuring plan, the layoffs have hit Indian employees in Bengaluru. Junior- to mid-level employees across functions such as sales and marketing, as well as those in the company's global business services (GBS) hub, which works with its global teams, have been impacted, according to at least three people aware of the development. "At least 100-150 will be retrenched from the commercial unit, which largely includes sales and marketing roles. They are expected to be in junior ...Read More >
New Delhi [India], April 1 (ANI): The Government of India on Thursday released details on the GLP -1 Drugs' use, risks, and regulation, according to an official press release. Diabetes is a chronic disease that occurs when the pancreas does not produce adequate insulin, or when the body cannot effectively use the insulin it produces, leading to high blood sugar. If left untreated, it can lead to complications like blindness, kidney failure, heart attacks, stroke and lower limb amputation. Insulin and glucagon are hormones produced by the pancreas that regulate blood sugar (glucose) levels. I ...Read More >
New Delhi, Dec 17 (PTI) Drug firm Granules India on Tuesday said its subsidiary has received approval from the US health regulator for a generic medication used to treat attention-deficit hyperactivity disorder. Granules Pharmaceuticals, Inc (GPI) has received approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Lisdexamfetamine Dimesylate chewable tablets, the drug firm said in a statement. The approved drug is available in multiple strengths; 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg, it added. The company's product is the generic ...Read More >
Srinagar, Aug 3: The Department of Archives, Archaeology and Museums on Sunday said that an ancient Shivling had been unearthed and safely housed in the SPS Museum Srinagar for public display. A statement of the Department of Archives, Archaeology and Museums issued here said that it was pleased to announce the discovery of an ancient Shivling carved from stone, measuring 137 cm in length and 160 cm in width, approximately dating back to the 10th Century CE, recovered during sand extraction by local labourers from the Jhelum River near the Army camp at Khanpora in Baramulla. The statement sa ...Read More >
Adani commits Rs 33,081 crore to Odisha projects. ShowQuick Read Summary is AI-generated, newsroom-reviewed * Adani Group commits Rs 33,081 crore for three major projects in Odisha * Projects include data center, thermal power plant, and cement plant near Cuttack * Data center in Bhubaneswar to support AI, cloud computing, and digital governance Did our AI summary help? Let us know. Switch To Beeps Mode New Delhi: The Adani Group pledged three large-scale infrastructure projects in Odis ...Read More >
New Delhi [India], August 25 (ANI): India's contract research, development, and manufacturing organisation (CRDMO) sector is emerging as one of the most dynamic growth stories in the global pharmaceutical landscape. According to a recent Jefferies India report, the country's CRDMO, which has already reached revenues of around USD 3 billion, has grown at a compound annual growth rate (CAGR) of 14 per cent over the past five years. The report highlights that India's CRDMO industry has caught the attention of global investors, with its market capitalization now standing at USD 40-50 billion. Whi ...Read More >
New Delhi [India], April 1 (ANI): The Government of India on Thursday released details on the GLP -1 Drugs' use, risks, and regulation, according to an official press release. Diabetes is a chronic disease that occurs when the pancreas does not produce adequate insulin, or when the body cannot effectively use the insulin it produces, leading to high blood sugar. If left untreated, it can lead to complications like blindness, kidney failure, heart attacks, stroke and lower limb amputation. Also Read | Patna Shocker: Woman Drugged With Sedative-Laced Drink and Gang-Raped on Pretext of Job Prom ...Read More >
Thiruvananthapuram, June 27 (UNI) Amid rising cases of diabetes, over 5 crore Indians remain undiagnosed, prompting urgent calls for regular screening and lifestyle changes. India faces an alarming diabetes prevalence of 11.4 per cent, with over 10 crore people currently living with the condition, Dr Naresh Purohit, Advisor for the National Programme for Prevention and Control of Diabetes, said. Quoting his recent scientific report published in the Australian Journal of Public Health, acclaimed physician pointed out that God's own country, 'Kerala', is witnessing a dramatic demographic shift ...Read More >
Bengaluru: Alembic Pharmaceuticals, Inc., the U.S. subsidiary of Alembic Pharmaceuticals Ltd., has acquired Utility Therapeutics Ltd. ("Utility") in a $12 million deal to strengthen its presence in the U.S. market. Alembic will begin the commercialization of Utility's recently FDA approved product Pivya® (pivmethecillam) for the treatment of uncomplicated urinary tract infections. Pivya® was approved by the FDA in April 2024. Commenting on the acquisition, Mr. Pranav Amin, Managing Director of Alembic Pharmaceuticals Limited, said: "This acquisition gives us a strategic entry into the special ...Read More >
Surat (Gujarat) [India], August 21: KP Group, a leading name in India's renewable energy sector, is stepping up its expansion with a clear goal of reaching 10 GW capacity by 2030. With projects already underway in Gujarat, the Group is working on projects in Rajasthan, Madhya Pradesh, Odisha, Andhra Pradesh and Maharashtra, supported by a strong order book and government partnerships. KP Group has signed memoranda of understanding with Gujarat, Odisha, Rajasthan and Madhya Pradesh for over 2.6 GW of renewable projects, while exploring new opportunities in other states. The Group has already e ...Read More >
MUMBAI, Sept 25 (Reuters) - Eli Lilly (LLY.N), opens new tab plans to bring its experimental oral weight-loss drug orforglipron to India as it sees market potential in the world's most populous nation, a senior executive said on Thursday. "I do think there is promise for products like that (orforpligron) in India, if it does get approved," Winselow Tucker, Lilly India's president said at an event in Mumbai. Tucker, however, did not indicate when Lilly plans to launch the drug. The drugmaker ha ...Read More >
India Diabetes Market: By Type; By Treatment Type; By Doses Form; Route of Administration; By End User; By Distribution Channel; Supplier Landscape; 2025-2034 The India diabetes market attained a value of approximately INR 316.00 Billion in 2024. The market is projected to grow at a compound annual growth rate (CAGR) of 16.00% during the forecast period of 2025-2034, reaching an estimated value of around INR 1394.01 Billion by 2034. The rising prevalence of diabetes, driven by sedentary lifestyles, changing dietary habits, and increasing obesity rates, is contributing significantly to the mar ...Read More >
Bengaluru : Emcure Pharmaceuticals Ltd. ("Emcure") and Sanofi India Limited ("SIL") today entered into an exclusive distribution and promotion agreement for SIL's oral anti-diabetic (OAD) products in India, effective immediately. Emcure will exclusively distribute and promote the Company's OAD range of products that include well-established brands like Amaryl® and Cetapin®. While SIL will continue to own and manufacture these brands across Sanofi's plants in India and internationally, Emcure will leverage its strengths to engage healthcare professionals and expand reach of these therapeutic ...Read More >